Enliven Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

ELVN$51.55+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of	As of
	September 30, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$101,732	$124,117
Marketable securities	375,833	189,323
Restricted cash	—	54
Prepaid expenses and other current assets	5,118	4,633
Total current assets	482,683	318,127
Property and equipment, net	399	458
Operating lease right-of-use assets	475	—
Deferred offering costs	217	—
Other long-term assets	7,101	7,175
Total assets	$490,875	$325,760
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,429	$1,342
Accrued expenses and other current liabilities	13,221	14,573
Total current liabilities	14,650	15,915
Long-term liabilities	103	—
Total liabilities	14,753	15,915
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none	—	—
Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 59,261,286 and 48,936,459 atSeptember 30, 2025 and December 31, 2024, respectively	59	49
Additional paid-in capital	793,341	553,213
Accumulated other comprehensive income	221	55
Accumulated deficit	(317,499)	(243,472)
Total stockholders’ equity	476,122	309,845
Total liabilities and stockholders' equity	$490,875	$325,760

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.